PT - JOURNAL ARTICLE AU - Paul Minh Huy Tran AU - Eileen Kim AU - Lynn Kim Hoang Tran AU - bin Satter Khaled AU - Wenbo Zhi AU - Shan Bai AU - Diane Hopkins AU - Melissa Gardiner AU - Jennifer Bryant AU - Risa Bernard AU - John Morgan AU - Bruce Bode AU - John Chip Reed AU - Jin-Xiong She AU - Sharad Purohit TI - T1DMicro: A Clinical Risk Calculator for Type 1 Diabetes Related Microvascular Complications AID - 10.1101/2021.09.01.21262996 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.01.21262996 4099 - http://medrxiv.org/content/early/2021/09/05/2021.09.01.21262996.short 4100 - http://medrxiv.org/content/early/2021/09/05/2021.09.01.21262996.full AB - Development of complications in type-1 diabetes patients can be reduced by modifying risk factors. We used a cross-sectional cohort of 1646 patients diagnosed with type 1 diabetes (T1D) to develop a clinical risk score for diabetic peripheral neuropathy (DPN), autonomic neuropathy (AN), retinopathy (DR), and nephropathy (DN). Of these patients, 199 (12.1%) had DPN, 63 (3.8%) had AN, 244 (14.9%) had DR, and 88 (5.4%) had DN. We selected five variables to include in each of the four microvascular complications risk models: age, age of T1D diagnosis, duration of T1D, and average systolic blood pressure and HbA1C over the last three clinic visits. These variables were selected for their strong evidence of association with diabetic complications in the literature and because they are modifiable risk factors. We found the optimism-corrected R2 and Harrell’s C statistic were 0.39 and 0.87 for DPN, 0.24 and 0.86 for AN, 0.49 and 0.91 for DR, and 0.22 and 0.83 for DN respectively.This tool (https://ptran25.shinyapps.io/Diabetic_Peripheral_Neuropathy_Risk) was built to help inform patients of their current risk of microvascular complications and to motivate patients to control their HbA1c and systolic blood pressure in order to reduce their risk of these complications.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the National Institutes of Health (R21HD050196, R33HD050196, and 2RO1HD37800) and JDRF (1-2004-661) to JXS. SP (2-2011-153, 10-2006-792 and 3-2004-195) and WZ (3-2009-275) were supported by Postdoctoral Fellowship and Career Development Award from JDRF. PMHT was supported by NIH/NIDDK fellowship (F30DK12146101A1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research was carried out according to The Code of Ethics of the World Medical Association (Declaration of Helsinki, 1997). All study participants gave written informed consent. The study was reviewed and approved by the institutional review board at Augusta University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon reasonable request to authors. All code are available on the Github page. https://github.com/pmtran5884/T1D_Complications